1994-2000 Universitaria

Título Obtenido: Médico – Homologado al español de licenciado en medicina.

Promedio: 8,82/10

Facultad de Ciencias Médicas –UBA. Ciudad Autónoma de Buenos Aires

2005 Título de especialista universitario en Medicina Interna. Universidad de Buenos Aires. Residencia en el Hospital de Clínicas José de San Martín, Buenos Aires.

2007 Título de especialista universitario en Gastroenterología. Universidad de Buenos Aires. Residencia de Gastroenterología en el Hospital de Clínicas José de San Martín – Homologado al título español de especialista en Aparato Digestivo en 2009.

ACTIVIDAD DOCENTE:

2018-actual Docente asociado a la Universidad Francisco de Vitoria.

2001 Adscrito a la docencia en Anatomía y Medicina Interna de la Facultad de Medicina de la Universidad de Buenos Aires. Cursado y aprobado hasta el tercer año de la carrera docente.

2001 Jefe de Trabajos Prácticos de Anatomía. Segunda Cátedra de Anatomía de la Facultad de Medicina de la Universidad de Buenos Aires.

2001 Jefe de Trabajos Prácticos de Farmacología Clínica. Facultad de Medicina. Universidad de Buenos Aires.

ACTIVIDAD LABORAL:

09/2011-Actual Jefe de Servicio de Aparato Digestivo, Hospital Universitario de Torrejón, Madrid, España.

2009-Actual Especialista en Aparato Digestivo – Hospital Quirón Sur, Madrid, España.

2009-2011 Especialista en Aparato Digestivo – Hospital Quirón Madrid.

2007- 2010 Becario en el Servicio de Aparato Digestivo, sección Enfermedad Inflamatoria Intestinal, Hospital Ramón y Cajal, Madrid.

2006-05/2007 Médico de Gedyt (Gastroenterología diagnóstica y terapéutica), Buenos Aires. Argentina. http://www.gedyt.com.ar/

2006-05/2007 Médico endoscopista de la sección Endoscopia Digestiva del Hospital Español,

Buenos Aires, Argentina.

2005-2007 Médico consultor de Best Doctors, Inc. Boston MA USA. http://www.bestdoctors.com

ÁREAS DE INTERÉS:

• Enfermedad inflamatoria intestinal.
• Endoscopia digestiva básica y avanzada.
• Gestión.
• Docencia

PARTICIPACIÓN EN ENSAYOS CLÍNICOS

A phase 2, randomized, parallel-group, double-blind, double-dummy, placebo-controlled, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of UTTR1147a compared with placebo and compared with vedolizumab in patients with moderate to severe ulcerative colitis

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease.

GED0507: A phase 2, randomized, placebo controlled, multicenter study to investigate the efficacy and safety of GED-0507-34-levo (GED0507) for treatment of subjects with active ulcerative colitis

CERTIFI / Protocol C0743T26: A Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Previously Treated with TNF Antagonist Therapy. N Engl J Med. 2012 Oct 18;367(16):1519-28

FATT II: Fistula Advanced Therapy Trial (II). Randomized, single-blind, placebo controlled multicenter phase III study to assess the efficacy and safety of expanded autologous adipose-derived stem cells (CX-401), for the treatment of complex perianal fistulas in perianal Crohn’s disease.

PENTASA in Active Crohn’s DiseasE (PEACE): A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6g/day (mesalazine, mesalamine) with placebo.

ATICCA: An Open Randomized Multicenter Clinical Investigation to Compare the Efficacy and Safety of Prednisone plus Adacolumn® GMA Aphaeresis versus Prednisone Alone in the Treatment of Patients with Mild or Moderately Active Steroid Dependent Ulcerative Colitis. Study code: Ada-UC-07-102.

CYSIF: A randomized multicenter, open-label multicenter study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis. Lancet. 2012 Dec 1;380(9857):1909-15.

SPD476: A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis. Gastroenterology. 2010 Apr;138(4):1286-96

AZTEC: Azathioprine for the treatment of early Crohn’s disease. A multicenter bouble blind placebo controlled trial. Gastroenterology. 2013 Oct;145(4):766-74.

PUBLICACIONES:

Ana Garcia Garcia de Paredes; Enrique Rodriguez de Santiago; Carlos Rodriguez-Escaja; Alicia Algaba; Jose Ignacio Cameo; Luisa De La Peña; Fernando Gomollon; Manuel Van Domselaar. 2020. Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study. Pancreatology. Elsevier. 3, pp.331-337.

Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in PatientsWith Inflammatory Bowel Disease: Results From the Eneida Registry. Inflamm Bowel Dis. 2020 Mar 4;26(4):606-616. doi: 10.1093/ibd/izz192.

Taxonera C, Ponferrada Á, Riestra S, Bermejo F, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Rivero M, Fernandez-Salazar L, Nantes Ó, Merino O, Alba C, Gisbert JP; CONVERT study group from GETECCU. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis. 12-11, pp.1270-1279.

Long-Term Safety of In Utero Exposure to Anti-TNF-alfa Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. American Journal of Gastroenterology. 113-3, pp.396-403.

Casanova MJ, Chaparro M, Molina B, Merino O, Batanero R, Dueñas-Sadornil C, Robledo P, Garcia-Albert AM, Gómez-Sánchez MB, Calvet X, Trallero MDR, Montoro M, Vázquez I, Charro M, Barragán A, Martínez-Cerezo F, Megias-Rangil I, Huguet JM, Marti-Bonmati E, Calvo M, Campderá M, Muñoz-Vicente M, Merchante A, Ávila AD, Serrano-Aguayo P, De Francisco R, Hervías D, Bujanda L, Rodriguez GE, Castro-Laria L, Barreiro-de Acosta M, Van Domselaar M, Ramirez de la Piscina P, Santos-Fernández J, Algaba A, Torra S, Pozzati L, López-Serrano P, Arribas MDR, Rincón ML, Peláez AC, Castro E, García-Herola A, Santander C, Hernández-Alonso M, Martín-Noguerol E, Gómez-Lozano M, Monedero T, Villoria A, Figuerola A, Castaño-García A, Banales JM, Díaz-Hernández L, Argüelles-Arias F, López-Díaz J, Pérez-Martínez I, García-Talavera N, Nuevo-Siguairo OK, Riestra S, Gisbert JP. 2017. Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease. Journal of Crohn's & colitis 2016 Dec 4. ISSN 1876-4479.

Taxonera C, Ponferrada Á, Bermejo F, Riestra S, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Alba C, Gisbert JP. 2017. Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.Journal of Crohn's & colitis. 11-7, pp.792-800. ISSN 1876-4479.

Iborra M, Pérez-Gisbert J, Bosca-Watts MM, López-García A, García-Sánchez V, López-Sanromán A, Hinojosa E, Márquez L, García-López S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-Gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P. 2017. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.Journal of gastroenterology. 52-7, pp.788-799. ISSN 1435-5922.

Chaparro M, Ramas M, Benítez JM, López-García A, Juan A, Guardiola J, Mínguez M, Calvet X, Márquez L, Fernández Salazar LI, Bujanda L, García C, Zabana Y, Lorente R, Barrio J, Hinojosa E, Iborra M, Cajal MD, Van Domselaar M, García-Sepulcre MF, Gomollón F, Piqueras M, Alcaín G, García-Sánchez V, Panés J, Domènech E, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP. 2017. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.The American journal of gastroenterology. 112-7, pp.1135-1143. ISSN 1572-0241.

Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Muñoz C, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, Gisbert JP. 2017. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. The American journal of gastroenterology. 112-1, pp.120-131. ISSN 1572-0241.

Guerra I, Pérez-Jeldres T, Iborra M, Algaba A, Monfort D, Calvet X, Chaparro M, Mañosa M, Hinojosa E, Minguez M, Ortiz de Zarate J, Márquez L, Prieto V, García-Sánchez V, Guardiola J, Rodriguez E, Martín-Arranz MD, García-Tercero I, Sicilia B, Masedo A, Lorente R, Rivero M, Fernández-Salazar L, Gutiérrez A, Van Domselaar M, López-SanRomán A, Ber Y, García-Sepulcre M, Ramos L, Bermejo G, P Gisbert J, Spanish GETECCU group (ENEIDA project).2016. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study. Inflammatory bowel diseases. 22-4, pp.894-901. ISSN 1536-4844.

Franco, AI.; Escobar, L.; García, XA.; Van Domselaar, M.; Achecar, LM.; Luján, DR.; García, MJ.2016. Mesalazine-induced eosinophilic pneumonia in a patient with ulcerative colitis disease: a case report and literature review.International journal of colorectal disease. 31-4, pp.927-929. ISSN 1432-1262.

Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2015 13-5, pp.847. ISSN 1542-7714.

Zabana, Y.; Garcia Planella, E.; Van Domselaar, M.; Mañosa, M.; Gordillo, J.; López Sanromán, A.; Cabré, E.; Domènech, E.2013. Predictors of favourable outcome in inflammatory Crohn's disease. A retrospective observational study.Gastroenterologia y hepatologia. 36-10, pp.616-623. ISSN 0210-5705.

Zabana, Y.; Garcia Planella, E.; Van Domselaar, M; Mañosa, M.; Gordillo, J.; López San Román, A.; Cabré, E.; Domènech, E.2013. Does active smoking really influence the course of Crohn's disease? A retrospective observational study.Journal of Crohn's &colitis. 7-4, pp.280-285. ISSN 1876-4479.

Vazquez Sequeiros, E.; Levy, MJ.; Van Domselaar, M; González Panizo, F.; Foruny Olcina, JR.; Boixeda Miquel, D.; Juzgado Lucas, D.; Albillos, A.2013. Diagnostic yield and safety of endoscopic ultrasound guided fine needle aspiration of central mediastinal lung masses.Diagnostic and therapeutic endoscopy. 2013, pp.150492. ISSN 1070-3608.

M Bastos Oreiro, C Castilla-Llorente, A L de la Guía, R de Paz, M Van Domselaar, J Nieto, A Rodriguez, D Gallardo, M Canales, GETH (Grupo Español de Trasplantes Hematopoyéticos y Terapia Celular). 2012 Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease. Bone marrow transplantation. 47-9, pp.1241-1242. ISSN 1476-5365.

Garcia Planella, E.; Mañosa, M.; Van Domselaar, M.; Gordillo, J.; Zabana, Y.; Cabré, E.; López San Román, A.; Domènech, E.2012. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 44-3, pp.206-210. ISSN 1878-3562.

Chaparro, M; Martínez Montiel, P.; Van Domselaar, M.; et al; Gisbert, JP.2012. Intensification of infliximab therapy in Crohn's disease: efficacy and safety.Journal of Crohn's & colitis. 6-1, pp.62-67. ISSN 1876-4479.

Fortea Ormaechea JI, González Lama Y, Casis, B., Chaparro M, López Serrano P, Van Domselaar M, Bermejo F, Pajares R, Ponferrada A, Vera MI, Martínez Montiel P, P Gisbert J, Pérez-Calle JL, López San Román A, Abreu L, Menchén LA, Marín Jiménez, I. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease 2011.The Madrid experience. Gastroenterologia y hepatologia. 34-7, pp.443-448. ISSN 0210-5705.

Zabana, Y.; Van Domselaar, M.; Garcia Planella, E.; Mañosa, M.; San Román, AL.; Gordillo, J.; Cabré, E.; Domènech, E.2011. Perianal disease in patients with ulcerative colitis: A case-control study.Journal of Crohn's &colitis. 5-4, pp.338-341. ISSN 1876-4479.

Teruel, Carlos; López San Román, Antonio; Bermejo, Fernando; Taxonera, Carlos; Pérez-Calle, José Lázaro; Gisbert, Javier P; Martín-Arranz, María; Ponferrada, Ángel; Van Domselaar, Manuel; Algaba, Alicia; Estellés, Jesús; López-Serrano, Pilar; Linares, Pablo M; Muriel, Alfonso. 2010. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines. The American journal of gastroenterology. 105-9, pp.2003-2008. ISSN 1572-0241.

Bermejo F, López-Sanromán A, Algaba A, Van-Domselaar M, P Gisbert J, García-Garzón S, Garrido E, Piqueras B, De La Poza G, Guerra I. 2010. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Alimentary pharmacology & therapeutics. 31-1, pp.120-124. ISSN 1365-2036.